Harnessing the full potential of the immune system: BioNTech’s vision for the future of cancer treatment
BioNTech is focused on translating decades of immunology expertise into the next era of cancer care. With more than 15 years of immunology and technological expertise, our ambition is to develop novel therapies that fundamentally transform how cancer is treated for every person.
From developing the first approved mRNA-based vaccine to building a diversified pipeline of novel oncology candidates in complementary therapeutic modalities, BioNTech’s journey has always centered around a singular belief: the immune system is a fundamental driver of therapeutic success in many diseases, including cancer.
Building on this foundation, we aim to set new standards of cancer care - powered by precision, enabled by immune intelligence, and tailored to reach patients.
At BioNTech, our long-standing mission is to harness the full potential of the human immune system to address some of the world’s most serious diseases. We are advancing our diversified oncology pipeline of investigational therapies into late-stage development and registrational trials, either alone or as combination therapies.
Redefining cancer treatment across tumor types
BioNTech’s multi-modality oncology pipeline consists of three complementary therapeutic approaches: mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies.
We believe that synergistic combinations can significantly contribute to addressing the complexity of cancer. Working together, our pipeline of investigational therapies is designed to address cancer from multiple angles: targeting multiple drivers of disease, empowering the immune system, and potentially preventing recurrence. BioNTech is advancing two priority pan-tumor programs:
- A next-generation immunomodulator, currently being evaluated in combination with antibody-drug conjugates (ADCs) or chemotherapy to enhance efficacy.
- mRNA cancer immunotherapy approaches, including both fully individualized therapies tailored to a patient’s unique tumor mutations or tumor type-specific therapies targeting shared neoantigens.
These programs aim to address the full continuum of cancer – from resected tumors in the adjuvant setting to later-stage advanced and metastatic cancers – across a range of solid tumors.
With more than 20 active Phase 2 and Phase 3 clinical trials, and a pipeline shaped by deep immunology and technological expertise, we are committed to advancing science with intention. We believe in scientific rigor, innovation and passion as the driving forces behind our work – and with every step forward, we move closer to our goal of delivering innovative next-generation cancer treatments.
Looking ahead
With the goal of product approvals in multiple indications over the next five years, BioNTech remains focused on developing immunotherapies that precisely target the right pathways for the right patients. With a pipeline rooted in scientific excellence and an unwavering commitment to patients, we are building a future where we believe the full potential of the immune system can be harnessed for every person with cancer.
Learn more about our priority programs and clinical pipeline below.
Explore more
Pipeline
